| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC ☆
|
Mok, T.S.K.
|
|
|
34 |
4 |
p. 377-388
|
article
|
| 2 |
Authors’ reply—A sensitivity analysis of the RAPIDO clinical trial
|
Dijkstra, E.A.
|
|
|
34 |
4 |
p. 446-447
|
article
|
| 3 |
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
|
Bayle, A.
|
|
|
34 |
4 |
p. 389-396
|
article
|
| 4 |
Editorial Board
|
|
|
|
34 |
4 |
p. iii
|
article
|
| 5 |
European cancer mortality predictions for the year 2023 with focus on lung cancer
|
Malvezzi, M.
|
|
|
34 |
4 |
p. 410-419
|
article
|
| 6 |
Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level
|
Bazhenova, L.
|
|
|
34 |
4 |
p. 327-332
|
article
|
| 7 |
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
|
Luen, S.J.
|
|
|
34 |
4 |
p. 397-409
|
article
|
| 8 |
Is it time for a paradigm shift in early rectal cancer treatment?
|
de Wilt, J.H.W.
|
|
|
34 |
4 |
p. 336-338
|
article
|
| 9 |
Liquid biopsy accelerates precision medicine
|
Amato, O.
|
|
|
34 |
4 |
p. 333-335
|
article
|
| 10 |
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit
|
Oosting, S.F.
|
|
|
34 |
4 |
p. 431-439
|
article
|
| 11 |
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Hendriks, L.E.
|
|
|
34 |
4 |
p. 358-376
|
article
|
| 12 |
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Hendriks, L.E.
|
|
|
34 |
4 |
p. 339-357
|
article
|
| 13 |
Reply to the Letter to the Editor ‘The Neonax study’ by M. W. Büchler and J. Neoptolemos
|
Seufferlein, T.
|
|
|
34 |
4 |
p. 443-445
|
article
|
| 14 |
Reply to the Letter to the Editor ‘The role of chemoradiotherapy in organ preservation for rectal cancer’ by L. Xie, Q. Chen, and J. Zhu
|
Serra-Aracil, X.
|
|
|
34 |
4 |
p. 440-442
|
article
|
| 15 |
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials ☆
|
Versluis, J.M.
|
|
|
34 |
4 |
p. 420-430
|
article
|
| 16 |
Table of Contents
|
|
|
|
34 |
4 |
p. i-ii
|
article
|
| 17 |
The NEONAX study
|
Büchler, M.W.
|
|
|
34 |
4 |
p. 442-443
|
article
|
| 18 |
The role of chemoradiotherapy in organ preservation for rectal cancer
|
Xie, L.
|
|
|
34 |
4 |
p. 440
|
article
|
Journal description